Stahel R A, Takvorian R W, Skarin A T, Canellos G P
Eur J Cancer Clin Oncol. 1984 Oct;20(10):1233-8. doi: 10.1016/0277-5379(84)90252-9.
Four patients with limited disease small cell carcinoma of the lung were treated with high-dose cyclophosphamide (120 mg/kg over days 1 and 2), BCNU (400 mg/m2 over days 1 and 2) and VP-16 (200 mg days 1-5) used as intensification treatment after conventional chemotherapy. To ameliorate hematopoietic toxicity, autologous bone marrow cells collected and cryopreserved prior to treatment were reinfused on day 8. In three patients clinical response was evaluable. Two achieved a complete remission: one died without evidence of tumor after 3 months; the other had a regional relapse after 6 months. One patient who had progression of disease on conventional chemotherapy was refractory to high-dose treatment. Three patients developed diffuse interstitial pneumonitis 3 weeks after treatment and two died of respiratory failure. High-dose intensification chemotherapy with autologous marrow reinfusion may complement the effects of standard combination chemotherapy in small cell carcinoma of the lung. The current status of this approach is reviewed.
4例局限性小细胞肺癌患者在接受常规化疗后，采用大剂量环磷酰胺（第1天和第2天剂量为120mg/kg）、卡莫司汀（第1天和第2天剂量为400mg/m²）和依托泊苷（第1 - 5天剂量为200mg）进行强化治疗。为减轻造血系统毒性，在治疗前采集并冻存的自体骨髓细胞于第8天回输。3例患者的临床反应可评估。2例达到完全缓解：1例在3个月后死亡，尸检未发现肿瘤；另1例在6个月后出现局部复发。1例在常规化疗期间病情进展的患者对大剂量治疗无效。3例患者在治疗后3周发生弥漫性间质性肺炎，2例死于呼吸衰竭。大剂量强化化疗联合自体骨髓回输可能会增强标准联合化疗对小细胞肺癌的治疗效果。本文对该治疗方法的现状进行了综述。
